MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study to evaluate numerous intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Major trial objectives had been to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis people, though among the explora... https://oxaliplatin91346.blogocial.com/new-step-by-step-map-for-imipenem-66794811